Debate Over Funding for Friedreich’s Ataxia Drug in Ireland

A new drug for Friedreich’s ataxia is recommended against funding by the NCPE due to its high cost versus benefits, sparking debate on its availability.

24 Aug, 04:30 — 24 Aug, 04:30

Post Share

Sources

Showing 1 of 1 sources

irish-independent23h ago

Luke O’Neill: Friedreich’s ataxia drug far from silver bullet, but it's the best option and should be funded

NCPE has recommended against paying for the treatment, because of its very high cost weighed against the benefits it brings

By Luke O'Neill

Read full article →

PERSPECTA

PERSPECTA

Debate Over Funding for Friedreich’s Ataxia Drug in Ireland

Sources

Luke O’Neill: Friedreich’s ataxia drug far from silver bullet, but it's the best option and should be funded

Related Stories

Trump Administration Proposes New H-1B Visa Fees and Asylum Visa Revocations

Canada Announces Retaliatory Tariffs Against US Amid Trade Dispute

US Tariffs Threaten Canadian Exports and Jobs, Prompting Political Backlash

Pakistan Army Chief Discusses Regional De-escalation with Iranian Officials

PERSPECTA